Osamu Nagayama - Chugai Pharmaceutical Chairman and CEO

CHGCF Stock  USD 39.14  2.42  5.82%   

Chairman

Mr. Osamu Nagayama was serving as Chairman of the Board and Representative Director in Chugai Pharmaceutical Co., Ltd. since March 2018. He is also serving as Chairman of the Board of Directors and Independent Director in Sony Corporationrationration. He joined the Company in November 1978. His previous titles include Chief Operating Officer, Chief Executive Officer, President, Deputy Chief Director of Development Planning, Managing Director, Vice President and Director in the Company. He used to work for LongTerm Credit Bank of Japan. since 2018.
Age 71
Tenure 6 years
Phone81 3 3281 6611
Webhttps://www.chugai-pharm.co.jp

Chugai Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

CHAIRMAN Age

Fritz GerberRoche Holding
88
Daniel VasellaNovartis AG ADR
65
Ulrich LehnerNovartis AG ADR
68
Sandra PetersonJohnson Johnson
58
Andre HoffmannRoche Holding
60
Enrico VanniNovartis AG ADR
70
Alex GorskyJohnson Johnson
64
John LechleiterEli Lilly And
61
Jorge MesquitaJohnson Johnson
56
Joaquin DuatoJohnson Johnson
61
Alex KrauerNovartis AG ADR
69
Joerg ReinhardtNovartis AG ADR
65
Thibaut MongonJohnson Johnson
51
Ashley McEvoyJohnson Johnson
50
Robert JDMerck Company
57
Jennifer TaubertJohnson Johnson
60
Leif JohanssonAstraZeneca PLC
67
Kenneth FrazierMerck Company
67
Paulus StoffelsJohnson Johnson
57
Leif JohanssonAstraZeneca PLC ADR
68
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. Chugai Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7664 people. Chugai Pharmaceutical Co [CHGCF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Chugai Pharmaceutical Leadership Team

Elected by the shareholders, the Chugai Pharmaceutical's board of directors comprises two types of representatives: Chugai Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chugai. The board's role is to monitor Chugai Pharmaceutical's management team and ensure that shareholders' interests are well served. Chugai Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chugai Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Osamu Nagayama, Chairman and CEO
Masayuki Oku, Independent Director
Franz Humer, Independent Director
Sophie KornowskiBonnet, Independent Director
Yasuo Ikeda, Independent Director
Harunori Yamazaki, Manager of Accounting Group in Finance & Accounting Unit
Yoshiyuki Yano, Executive Officer, Director of Human Resources
William Anderson, Director
Tatsuro Kosaka, President, COO and Representative Director
Motoo Ueno, Vice Chairman of the Board, Representative Director
Toshihiko Komori, Executive Officer, Assistant Manager of Project & Life Cycle Management Unit, Director of R&D Portfolio
Mamoru Togashi, Executive Officer, Director of Human Resources, Senior Manager of Human Resources Division
James Sabry, Director
Yutaka Tanaka, Managing Executive Officer, Manager of Life Circle Management and Marketing Unit
Daniel ODay, Independent Director
Minoru Watanabe, Executive Officer, Director of Business Planning
Tadahiko Sato, Executive Officer, Senior Manager of Tokyo 1st Office
Shinji Hidaka, Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit
Tetsuya Yamaguchi, Executive Officer, Director of Business Development
Hitoshi Kuboniwa, Executive Officer, Chief Director of Pharmaceutics Producing
Masaaki Tohaya, Managing Executive Officer, Chief Director of Sales
Tsunanori Sato, Executive Officer, Chief Director of Sales
Toshiaki Itagaki, VP and General Manager of Fin. and Accounting Department
Junichi Ebihara, VP and General Manager of Legal Department
Toshiya Sasai, Exec Department
Koichi Nishikawa, Executive Officer, Deputy Chief Director of Sales, Director of Marketing Planning
Osamu Okuda, Executive Officer, Director of Business Planning
Yoshiaki Ohashi, Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit
Yoko Kitagawa, Manager of Consolidated Financial Group in Finance & Accounting Unit
Christoph Franz, Director
Shinya Unno, Managing Executive Officer, Director of Business Planning
Hiroyuki Matsumoto, Executive Officer, Senior Manager of South Kanto Office in Main Sales Unit
Satoko Shisai, Executive Officer, Senior Manager of IT
Keiji Kono, Executive Officer, Senior Manager of IT Division
Hisafumi Okabe, VP and General Manager of Research Division
Hisanori Takanashi, Executive Officer, Chief Director of Clinical Development
Hiroshi Murata, Executive Officer, Chief Director of Pharmaceutical Technology
Yoichiro Ichimaru, Independent Director
Yoshio Itaya, CFO, Executive VP, General Manager of Fin. Supervisory Division and Director
Masahiko Uchida, Gen Department
Yasushi Ito, Executive Officer, Chief Director of Clinical Development
Susumu Kato, Executive Officer, Senior Manager of Tokyo First Office
Mitsuru Kikuchi, Managing Executive Officer, Director of External Investigation

Chugai Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Chugai Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Chugai Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chugai Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chugai Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Chugai Pink Sheet

  0.64PTAIF PT Astra InternationalPairCorr
  0.48NVSEF Novartis AGPairCorr
  0.47TLK Telkom Indonesia Tbk Financial Report 26th of April 2024 PairCorr
The ability to find closely correlated positions to Chugai Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chugai Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chugai Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chugai Pharmaceutical Co to buy it.
The correlation of Chugai Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chugai Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chugai Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chugai Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chugai Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Chugai Pink Sheet analysis

When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Please note, there is a significant difference between Chugai Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chugai Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chugai Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.